March 3, 2026Open Access

Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer

Key Points

Enhanced tumoricidal activity observed with bispecific CAR-T targeting CD155 and ROR1, indicating better efficacy.
Durable effects highlight the potential of dual-targeted therapies for improved outcomes in ovarian cancer.
Analysis involved a bispecific CAR-T approach focused on dual targeting, demonstrating elevated therapeutic potential.
Findings suggest that targeting CD155 may enable more effective strategies against ovarian cancer tumors.

Abstract

CD155 emerges as a promising therapeutic target for CAR-T therapy in OC. The bispecific CAR-T construct that co-targets CD155 and ROR1 demonstrates superior and durable tumoricidal activity, offering new perspectives on OC targeted therapy.

Bookmark

View Full Paper

Cite This Study

Ye et al. (Tue,) studied this question.

synapsesocial.com/papers/69a75a7fc6e9836116a205f8 https://doi.org/https://doi.org/10.1007/s00262-025-04283-x

Bookmark

View Full Paper